Premium
[P2–041]: POTENTIAL THERAPEUTIC SYSTEM FOR ALZHEIMER's DISEASE BY REMOVING BLOOD Aβ: EFFECTS OF BLOOD PURIFICATION PERIOD ON Aβ REMOVAL EFFICIENCIES IN HEMODIALYSIS PATIENTS
Author(s) -
Morikawa Hiroshi,
Tomizawa Hiroshi,
Kawaguchi Kazunori,
Suzuki Nobuo,
Ohashi Norimi,
Sakata Miwa,
Mineshima Michio,
Sobajima Hiroshi,
Hasegawa Midori,
Mizuno Masao,
Yuzawa Yukio,
Kitaguchi Nobuya
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.689
Subject(s) - medicine , hemodialysis , dialysis , surgery , anesthesia
active (VR with no treadmill, treadmill with non-specific cognitive stimulation) and one passive (waitlist) control conditions in a single-blind, parallel group, randomized controlled design. Participants in active groups train for 45 min. twice/week for 12 weeks. Primary outcomes are changes in memory performance and cerebral blood flow (CBF; MRI arterial spin labeling) immediately following training and at 6 months. Results:Baseline (mean6SD) demographic, clinical and cognitive characteristics of the first 10 participants: age 57.467.2 years, education: 15.862.9 years, 4 female; MMSE 28.561.1. On SF36 health status scales (scale:0-100; 1001⁄4no disability), mean6SD ranged from 62.0618.1 (energy/fatigue) to 95.068.2 (physical functioning). Memory scores: RAVLT Trial 1 6.861.9, Trial 5 11.262.4, Delayed recall: 10.263.2; Logical Memory I: 14.663.8, Logical Memory II: 13.664.1. Scores were within the normal range using accepted norms. Conclusions:Non-pharmacologic trainingmay be administered prior to symptom onset when prevention may be possible. An ecologically valid VR setting that mimics complex demands of everyday life may prove an ideal cognitive training environment that augments transfer. Though VR training has benefited clinical cohorts, benefit in asymptomatic high-risk individuals is relatively unknown. Further, CBF may be a key marker of cognitive benefits, as it has shown sensitivity to cognitive training in healthy seniors and hypoperfusion in individuals with AD family history. This trial may define a new prophylactic paradigm for AD, adaptable for home-based application in high risk individuals. By AAIC 2017 we anticipate demographic, cognitive and CBF data for 30 participants.